EC Number   |
Protein Variants |
Reference |
|---|
   3.1.4.53 | A590C |
mutation has no significant influence on substrate affinity or specificity |
686032 |
| 3.1.4.53 | D440A |
unlike wild type enzyme, the mutant enzyme shows activity with cGMP |
686032 |
| 3.1.4.53 | D440N |
unlike wild type enzyme, the mutant enzyme shows activity with cGMP |
686032 |
| 3.1.4.53 | D448N |
mutation in conserved active site residue, loss of enzyme function does not affect steady-state acetylcholine release or reception |
680022 |
| 3.1.4.53 | D63A |
the mutant shows less than 0.1% of wild type CpdA activity |
712298 |
| 3.1.4.53 | F484Y |
mutation has no significant influence on substrate affinity or specificity |
686032 |
| 3.1.4.53 | H23A |
the mutant shows less than 0.1% of wild type CpdA activity |
712298 |
| 3.1.4.53 | H305P |
the mutation is associated with micronodular adrenocortical disease |
686518 |
| 3.1.4.53 | L391A |
mutation has no significant influence on substrate affinity or specificity |
686032 |
| 3.1.4.53 | more |
enzyme knock-down by RNAi reveals that it may be complemented by isoform PDEB1, but simultaneous ablation of PDEB1 and PDEB2 leads to cell death in bloodstream form trypanosomes. In vivo application of RNAi completely prevents infection and eliminates ongoing infections |
679729 |
